InsiderTrades.com logo
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.

Craig Johnson Biography and Net Worth

Director of Mirati Therapeutics
  • LinkedIn
  • Phone
  • Email
  • Website


Craig currently serves as a director of Heron Therapeutics, Inc., La Jolla Pharmaceutical Company and Odonate Therapeutics, Inc. Craig has served as a member of the Mirati Board of Directors since 2013.

Craig served as a director of GenomeDx Biosciences, Inc. from 2015 to 2018, Adamis Pharmaceuticals Corporation from 2011 to 2014, and Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012. Between 2004 and 2009, Craig served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. Afterwards, he was Vice President of a wholly owned subsidiary of Raptor Pharmaceuticals Corp until 2010. From 1994 to 2004, he held various positions at MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations.

Craig received a B.B.A. degree in accounting from the University of Michigan-Dearborn and practiced as a Certified Public Accountant with Price Waterhouse, now PricewaterhouseCoopers.

What is Craig A. Johnson's net worth?

The estimated net worth of Craig A. Johnson is at least $210,733.00 as of April 6th, 2021. Mr. Johnson owns 3,590 shares of Mirati Therapeutics stock worth more than $210,733 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Johnson may own. Learn More about Craig A. Johnson's net worth.

How do I contact Craig A. Johnson?

The corporate mailing address for Mr. Johnson and other Mirati Therapeutics executives is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. Mirati Therapeutics can also be reached via phone at (858) 332-3410 and via email at [email protected]. Learn More on Craig A. Johnson's contact information.

Has Craig A. Johnson been buying or selling shares of Mirati Therapeutics?

Craig A. Johnson has not been actively trading shares of Mirati Therapeutics in the last ninety days. Most recently, Craig A. Johnson sold 15,000 shares of the business's stock in a transaction on Thursday, January 21st. The shares were sold at an average price of $211.55, for a transaction totalling $3,173,250.00. Following the completion of the sale, the director now directly owns 18,475 shares of the company's stock, valued at $3,908,386.25. Learn More on Craig A. Johnson's trading history.

Who are Mirati Therapeutics' active insiders?

Mirati Therapeutics' insider roster includes Charles Baum (CEO), Bruce Carter (Director), Julie Cherrington (Director), Jamie Christensen (EVP), Daniel Faga (COO), Henry Fuchs (Director), Benjamin Hickey (EVP), Craig Johnson (Director), and Vickie Reed (CAO). Learn More on Mirati Therapeutics' active insiders.

Are insiders buying or selling shares of Mirati Therapeutics?

In the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 7,438 shares worth more than $433,243.25. The most recent insider tranaction occured on January, 16th when EVP Benjamin Hickey sold 1,597 shares worth more than $94,254.94. Insiders at Mirati Therapeutics own 3.3% of the company. Learn More about insider trades at Mirati Therapeutics.

Information on this page was last updated on 1/16/2024.

Craig A. Johnson Insider Trading History at Mirati Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/21/2021Sell15,000$211.55$3,173,250.0018,475View SEC Filing Icon  
4/20/2020Sell15,000$93.00$1,395,000.0017,000View SEC Filing Icon  
1/29/2019Sell17,000$61.46$1,044,820.007,000View SEC Filing Icon  
See Full Table

Craig A. Johnson Buying and Selling Activity at Mirati Therapeutics

This chart shows Craig A Johnson's buying and selling at Mirati Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mirati Therapeutics Company Overview

Mirati Therapeutics logo
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $58.70
Low: $58.70
High: $58.70

50 Day Range

MA: $58.82
Low: $58.70
High: $59.28

2 Week Range

Now: $58.70
Low: $27.30
High: $64.41

Volume

N/A

Average Volume

2,758,857 shs

Market Capitalization

$4.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.